磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical)(PC-SOD) - 药物靶点：SOD1_在研适应症：心肌再灌注损伤_专利_临床

概要

基本信息

药物类型

酶

别名

CY

靶点

SOD1

作用机制

SOD1调节剂(超氧化物歧化酶调节剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评-

登录后查看时间轴

关联

7

项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的临床试验

JPRN-jRCT2031210466

/ Completed临床2期IIT

Placebo-controlled, double-blind, randomized phase II study of PC-SOD for chemotherapy-induced peripheral neuropathy

开始日期2022-01-19

申办/合作机构-

NCT03995732

/ Unknown status临床2期

Efficacy and Safety Evaluation of Phosphatidyl Choline Cu/Zn Superoxide Dismutase (PC-SOD) for Injection in Reducing Myocardial Reperfusion Injury: a Multicenter, Randomized, Single-blind, Placebo-controlled Dose-finding Study

The current study aims to evaluate different doses of PC-SOD injections for efficacy and safety in comparison to placebo, in order to provide a basis for future clinical trials in terms of experimental design and dose selection.

开始日期2019-06-18

申办/合作机构

北京泰德制药股份有限公司

[+1]

CTR20160765

/ Completed临床1期

CY单中心、随机双盲、安慰剂平行对照、剂量递增单次静脉给药健康志愿者耐受性及药代动力学临床试验

评价CY在健康成年志愿者中，单次静脉推注给药的耐受性和药代动力学行为。

开始日期2016-12-19

申办/合作机构

北京泰德制药股份有限公司

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的临床结果

登录后查看更多信息

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的转化医学

登录后查看更多信息

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的专利（医药）

登录后查看更多信息

3,356

项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的文献（医药）

2024-12-31·Gynecological Endocrinology

Treatment of ovarian damage induced by chemotherapeutic drugs in female rats with G-CSF and platelet-rich plasma(PRP): an immunohistochemical study correlation with novel marker INSL-3

Article

作者: Ates, Seda ; Ozcan, Pınar ; Tok, Olgu Enis ; Karasu, Ayse Filiz Gokmen ; Okten, Sabri Berkem ; Taha, Havva Sevde ; Tanoglu, Fatma Basak ; Cetin, Caglar

OBJECTIVETo assess the impacts of Platelet-Rich Plasma(PRP) and Granulocyte Colony-Stimulating Factor(G-CSF) on a rat model with induced ovarian follicular damage caused by cyclophosphamide(Cy).MATERIALS AND METHODSForty-two Sprague-Dawley rats were randomly allocated into seven distinct groups as; Group 1(control): NaCl intraperitoneal (IP) injection was administered on days D1, D7, and D14. Group 2(Cy):Cy IP injection on D1 + NaCl IP injection on D7 and D14 were administered. Group 3(PRP): PRP IP injection on D1,D7 and D14 were administered. Group 4(Cy + PRP):Cy IP injection on D1 and PRP IP injection on D1, D7 and D14 were administered. Group 5(G-CSF): G-CSF IP injection on D1, D7 and D14 were administered. Group 6(Cy + G-CSF):Cy IP injection on D1+ G-CSF IP injection on D1, D7 and D14 were administered. Group 7(Cy + PRP + G-CSF):Cy IP injection on D1+ PRP IP injection on D1,D7 and D14+ G-CSF IP injection on D1,D7 and D14 were administered. Follicular number, histological scores of AMH and INSL3 stained follicles at different stages of follicular development, and serum Anti-Müllerian hormone(AMH) were evaluated.RESULTSThe primary, secondary, and antral follicle intensity scores for AMH-positive staining were most prominent in Groups 3 and 5. There was no significant difference between groups 4, 6 and 7 compared to group 1 in terms of follicule counts and AMH staining. The intensity scores of AMH-positive staining follicles were notably reduced in group 2 compared to groups 4, 6, and 7, with a significant difference (p < .01). Among the groups, group 2 exhibited the least intense antral follicle staining for INSL3, displaying a significant difference(p < .01) compared to the remaining groups.CONCLUSIONSAutologous PRP and G-CSF might protect ovarian function in the face of ovarian damage caused by Cy-induced effects.

2024-07-01·Transplantation and Cellular Therapy

Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma

Article

作者: Schuster, Stephen J ; Chong, Emeline R ; Ruella, Marco ; Weber, Elizabeth ; Therwhanger, Dylan ; Chong, Elise A ; Garfall, Alfred L ; Barta, Stefan K ; Stefano, Natalie ; Gerson, James N ; Landsburg, Daniel J ; Ghilardi, Guido ; Frey, Noelle V ; Porter, David L ; Nasta, Sunita D ; Svoboda, Jakub ; Paruzzo, Luca ; Fraietta, Joseph A

Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory mantle cell lymphoma (MCL). During a fludarabine shortage, we used bendamustine as an alternative to standard cyclophosphamide/fludarabine (cy/flu) lymphodepletion (LD) prior to brexu-cel. We assessed MCL patient outcomes as well as CAR T-cell expansion and persistence after brexu-cel following bendamustine or cy/flu LD at our center. This was a retrospective single institution study that utilized prospectively banked blood and tissue samples. Clinical efficacy was assessed by 2014 Lugano guidelines. CAR T-cell expansion and persistence in peripheral blood were assessed on day 7 and at ≥month 6 for patients with available samples. Seventeen patients received bendamustine and 5 received cy/flu. For the bendamustine cohort, 14 (82%) received bridging therapy and 4 (24%) had CNS involvement. Fifteen patients (88%) developed CRS with 4 (24%) ≥grade 3 events. Six (35%) patients developed ICANS with 4 (24%) events ≥grade 3. No patient had ≥grade 3 cytopenias at day 90. Best objective (BOR) and complete response (CRR) rates were 82% and 65%, respectively. At 24.5 months median follow-up, 12-month progression-free survival (PFS) was 45%, 24-month PFS was 25%, and median duration of response was 19 months. Median OS was not reached. BOR was 25% (1/4) for patients with CNS involvement. CAR transgene expansion after bendamustine LD was observed on day 7 in all (4/4) patients tested and persisted at ≥6 months (2/2), regardless of response. Bendamustine LD before brexu-cel for MCL is feasible and safe with a lower frequency and shorter duration of cytopenias than reported for cy/flu. Both CAR T-cell expansion and persistence were observed after bendamustine LD. Outcomes appear comparable to the real world outcomes reported with cy/flu LD.

2024-06-01·Hormone and Metabolic Research

Islet Like Cells Induced from Umbilical Cord Mesenchymal Stem Cells with Neonatal Bovine Pancreatic Mesenchymal Exosomes for Treatment of Diabetes Mellitus

Article

作者: Han, Xia ; Li, Xin ; Zhaorigen, Bayalige ; Yun, Feiyu ; Yun, Sheng

AbstractTo investigate the safety and efficacy of the islet-like cell (cell) induced from human umbilical cord mesenchymal stem cell (UCMSC) with different methods for the treatment of diabetic animal model. UCMSCs were induced to βcells with cytokines (CY) and neonatal bovine pancreatic mesenchymal cell exosomes (Ex) combined with CY (EX+CY). The insulin secretion of UCMSC and βcell was measured with ELISA when the cells were growing in different concentrations of glucose media for different times. UCMSCs (4×105) and the same number of cells prepared with two methods were transplanted to type I diabetic rat models. UCMSCs could be induced into islet βcells by CY or EX+CY in vitro. The insulin secretion of the prepared β cells growing in 25.0 mM glucose medium was over 5-fold of that in 6.0 mM glucose. The transplantation of the βcells to type I diabetic rat models could reduce the blood glucose and prolong the survival time. The β cells induced by EX+CY had much more significant effects on decreasing blood glucose and increasing survival time (p<0.01). The cells did not affect blood sugar level and had no serious side-effects in human health. UCMSC could be induced to islet βcells with either CY or EX+CY. The transplantation of the induced islet βcells could reduce blood glucose and prolong the survival time of diabetic animal models. Although the cells induced with EX+CY had more significant effects on diabetic rats, they did not affect blood glucose level and had no serious side-effects in human health.

100 项与磷脂化重组人铜锌超氧化物歧化酶(Beijing Tide Pharmaceutical) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心肌再灌注损伤	临床2期	中国	北京泰德制药股份有限公司	2019-05-23
心肌梗塞	临床前	中国	北京泰德制药股份有限公司	2016-12-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2023	N/A	血液肿瘤	85	Intermediate-dose AraC+G-CSF	繭繭壓糧糧製蓋襯壓製(簾膚構淵構製觸製遞膚) = 淵壓膚積鬱衊蓋鬱鬱齋衊鹹鹹憲糧鏇顧獵範廠 (膚簾膚醖選淵鬱壓遞艱 )	-	2023-06-08
				Cy+G-CSF	繭繭壓糧糧製蓋襯壓製(簾膚構淵構製觸製遞膚) = 獵鬱築構窪憲糧鏇憲餘衊鹹鹹憲糧鏇顧獵範廠 (膚簾膚醖選淵鬱壓遞艱 )
P552 (EBMT2022)	N/A	多发性骨髓瘤	156	24 hours continuous infusion of Cy	(壓鑰簾築淵構糧構鬱衊) = 廠鹹繭蓋鑰壓齋積獵願築鏇鹹鏇遞繭壓餘壓膚 (鬱網顧鬱鹹範壓築築網 ) 更多	-	2022-03-19
				short time (4-6 hours) infusion of Cy	(壓鑰簾築淵構糧構鬱衊) = 淵膚獵餘選遞鑰衊衊窪築鏇鹹鏇遞繭壓餘壓膚 (鬱網顧鬱鹹範壓築築網 ) 更多
ASCT1201 (EHA2020)	临床2期	多发性骨髓瘤巩固 \| 维持	54	CBD regimen	淵窪醖齋簾範膚網築憲(範鏇鹽獵齋淵壓餘艱壓) = 窪膚願襯構觸築製製憲鏇鹹夢衊鹽獵醖廠觸膚 (網範鹽範觸衊艱選夢積, 42.5%>69.3%) 更多	-	2020-05-14
				CY and VAD regimen	淵窪醖齋簾範膚網築憲(範鏇鹽獵齋淵壓餘艱壓) = 齋繭鏇觸壓簾鹽鬱鏇繭鏇鹹夢衊鹽獵醖廠觸膚 (網範鹽範觸衊艱選夢積 ) 更多
ASCO2014	N/A	多发性骨髓瘤	24	TBI8/CY	(糧網遞淵選膚齋鬱鬱糧) = 鬱醖繭憲製鏇壓廠醖選積鏇鑰衊淵壓願憲襯膚 (蓋遞壓鹽夢網蓋壓範餘 ) 更多	-	2014-05-20
Tandem Meetings ASTCT and CIBMTR2010	N/A	非霍奇金淋巴瘤	56	Cy 4gm/m2+G-CSF	鏇廠顧簾餘顧願艱襯餘(顧艱膚窪淵襯壓醖願顧) = 鑰艱積蓋築鬱積願糧簾鹽鏇醖願願願網鹹齋繭 (廠簾範繭夢範鑰淵淵網 )	-	2010-02-01
				Cy 2gm/m2+G-CSF	鏇廠顧簾餘顧願艱襯餘(顧艱膚窪淵襯壓醖願顧) = 鑰範鹹憲壓遞壓獵齋鬱鹽鏇醖願願願網鹹齋繭 (廠簾範繭夢範鑰淵淵網 )
Tandem Meetings ASTCT and CIBMTR2010	N/A	多发性骨髓瘤	72	Cy 4gm/m2+G-CSF	艱壓遞觸壓繭膚鏇繭遞(齋鑰遞廠遞壓簾淵簾糧) = 膚獵鹽廠襯廠膚艱構鹹襯簾醖顧築願衊鹽艱膚 (範鬱願構鬱廠膚夢鹹夢 ) 更多	不佳	2010-02-01
				Cy 2gm/m2+G-CSF	艱壓遞觸壓繭膚鏇繭遞(齋鑰遞廠遞壓簾淵簾糧) = 壓築獵廠構遞顧糧顧廠襯簾醖顧築願衊鹽艱膚 (範鬱願構鬱廠膚夢鹹夢 ) 更多
Tandem Meetings ASTCT and CIBMTR2009	临床2期	血液肿瘤	-	Personalized CY dosing	膚糧願淵範簾構蓋鬱繭(鬱願鑰鬱壓製壓襯淵衊) = 齋憲廠願鹽憲艱餘鹽艱選襯鬱艱鏇鹽鹹窪網鑰 (選窪獵蓋醖壓鑰餘餘鑰, 0.7 ~ 8.8)	积极	2009-02-01
				Standard CY dosing	膚糧願淵範簾構蓋鬱繭(鬱願鑰鬱壓製壓襯淵衊) = 鹽鹹顧遞壓夢簾範淵鏇選襯鬱艱鏇鹽鹹窪網鑰 (選窪獵蓋醖壓鑰餘餘鑰, 0.4 ~ 18.3)